Image de couverture de Drugs and the FDA

Drugs and the FDA

Safety, Efficacy, and the Public's Trust

Écouter un extrait
La meilleure offre de la saison

0,99 €/mois pendant 3 mois + 15 € de crédit Audible

Renouvellement automatique à 6,99 €/mois après 3 mois. Annulation mensuelle possible.
Profiter de l’offre
L'offre prend fin le 28 décembre 2026.
Plus d'offres

Drugs and the FDA

De : Mikkael A. Sekeres
Lu par : Mike Lenz
Profiter de l’offre

Renouvellement automatique à 6,99 €/mois après 3 mois. Annulation mensuelle possible. L'offre se termine le 28 décembre 2026.

Acheter pour 17,89 €

Acheter pour 17,89 €

La meilleure offre de la saison | 0,99 €/mois pendant les 3 premiers mois + 15 € de crédit Audible

6,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
À propos de ce titre

Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate United States authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA's cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient advocacy, for the government to take responsibility for ensuring the efficacy and safety of drugs and medical devices.

Before the FDA existed, drug makers could hawk any potion, claim treatment of any ailment, and make any promise on a label. But then, throughout the twentieth century, the government was forced to take action when children were poisoned by contaminated diphtheria and smallpox vaccines, an early antibiotic contained antifreeze, a drug prescribed for morning sickness in pregnancy caused babies to be born disfigured, and access to AIDS drugs was limited to a few clinical trials while thousands died. Sekeres describes all these events against the backdrop of the contentious 2011 hearings on the breast cancer drug Avastin, in which he participated as a panel member.

©2022 Mikkael A. Sekeres (P)2023 Tantor
Recht
adbl_web_anon_alc_button_suppression_t1
Aucune critique pour le moment